高嘉敏,舒正玉

肿瘤免疫治疗是通过调动人体免疫系统来杀死癌细胞的治疗方法，是近十几年快速发展起来的新型疗法。当前，肿瘤免疫疗法在交叉学科的融合发展下呈现多样化新兴发展态势，为现代临床医疗研究的重要一环，其治疗能力日益凸显，有望成为治疗多种癌症的标准。文章介绍了两种典型的肿瘤免疫疗法，分析最新的研究进展，并对未来进行展望，以期为肿瘤免疫治疗药物的研发提供参考。

肿瘤；肿瘤免疫治疗；免疫检查点；CAR-T

[1] 李晓瑞,尚凤琴,王建勋.CAR-T疗法在治疗肿瘤免疫逃逸中的研究进展[J].现代肿瘤医学,2021,29(15):2735-2738. [2] Z.Tang,D.Li,S.Hou,et al,The cancer exosomes:clinical implications,applications and challenges[J].Int.J.Cancer 146(11)(2020)2946–2959. [3] Sing S,Hassan D,Aldawsari H,et al.Immune checkpoint inhibitors:a promising anticancer therapy[J].Drug Discov Today,2020,25(1):223-229. [4] K.S.Peggs,S.A.Quezada,C.A.Chambers,A.J.Korman,J.P.Allison,Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to theantitumor activity of anti–CTLA-4 antibodies[J].Exp.Med.206(2009)1717–1725. [5] S.C.Wei,J.H.Levine,A.P.Cogdill,et al,Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade[J].Cell 170(2017)1120–1133. [6] J.S.Weber,S.P.D'Angelo,D.Minor,et al.Larkin,Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment(CheckMate 037):a randomised,controlled,open-label,phase 3 trial,Lancet Oncol.16(2015)375–384. [7] R.L.Ferris,G.Blumenschein,J.Fayette,et al.Nivolumab for recurrent squamous cell carcinoma of the head and neck[J].N.Engl.J.Med.375(2016)1856–1867. [8] Zhang T,Cao L,Xie J,et al.Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials:a meta-analysis[J].Oncotarget.2015;6(32):33961–71. [9] 李龙,谢成英,郑明月,蒋华良.肿瘤免疫治疗研究进展[J].自然杂志,2021,43(06):391-399.

点击下载PDF